title: [Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases].
abstract: BACKGROUND
  TNFalpha blockers have recently extended the therapeutic arsenal available in dermatology. However, dermatologists must be informed of their potential adverse dermatological effects. While the chief adverse effect of TNFalpha blockers is risk of infection, cutaneous adverse effects have not yet been clearly elucidated and publications on this topic are few and far between. The aim of our study is to report various dermatological problems noted during treatment with TNFalpha blockers.
  
  
  METHODS
  This was a retrospective study of patient files. The study population comprised patients receiving TNFalpha blockers and presenting cutaneous reaction, and seen in the dermatology department between August 2001 and December 2004.
  
  
  RESULTS
  Eleven patients were included. The following cutaneous reactions were seen: delayed skin rash (1 case), lupus syndrome (1 case), cutaneous vasculitis (2 cases), palmoplantar pustulosis (2 cases), psoriasis vulgaris (1 case), atopic dermatitis (1 case), lichenoid rash (1 case), purpuric capillaritis (1 case) and melanoma (1 case).
  
  
  CONCLUSIONS
  The cutaneous manifestations seen represented a wide range of different clinical pictures. Dermatologists must be aware of these potential adverse effects. Future improvement of knowledge of the physiopathological mechanisms as well as the institution of prospective cohort studies should provide clearer guidance on the management of such symptoms.
authors.affiliation: Clinique de Dermatologie, Hôpital Claude Huriez, CHRU Lille, Lille Cedex.
authors.forename: D
authors.initials: D
authors.lastname: Lebas
authors.forename: D
authors.initials: D
authors.lastname: Staumont-Sallé
authors.forename: E
authors.initials: E
authors.lastname: Solau-Gervais
authors.forename: R-M
authors.initials: RM
authors.lastname: Flipo
authors.forename: E
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000068800:Etanercept; D005076:Exanthema / Q000139:chemically induced; D036981:Fasciitis, Plantar / Q000139:chemically induced; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D012189:Retrospective Studies; D012871:Skin Diseases / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014657:Vasculitis / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept